{"protocolSection":{"identificationModule":{"nctId":"NCT00958243","orgStudyIdInfo":{"id":"CSLCT-CAL-09-62"},"organization":{"fullName":"Seqirus","class":"INDUSTRY"},"briefTitle":"A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA","officialTitle":"A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population"},"statusModule":{"statusVerifiedDate":"2018-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-08"},"primaryCompletionDateStruct":{"date":"2009-11","type":"ACTUAL"},"completionDateStruct":{"date":"2010-04","type":"ACTUAL"},"studyFirstSubmitDate":"2009-08-12","studyFirstSubmitQcDate":"2009-08-12","studyFirstPostDateStruct":{"date":"2009-08-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-07-13","resultsFirstSubmitQcDate":"2011-07-13","resultsFirstPostDateStruct":{"date":"2011-08-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-04-25","lastUpdatePostDateStruct":{"date":"2018-05-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Seqirus","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425 (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population."},"conditionsModule":{"conditions":["Influenza"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":473,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo","interventionNames":["Biological: Placebo"]},{"label":"CSL425 (7.5 mcg)","type":"EXPERIMENTAL","description":"7.5 mcg of hemagglutinin antigen per dose","interventionNames":["Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)"]},{"label":"CSL425 (15 mcg)","type":"EXPERIMENTAL","description":"15 mcg of hemagglutinin antigen per dose","interventionNames":["Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)"]}],"interventions":[{"type":"BIOLOGICAL","name":"CSL's 2009 H1N1 Influenza Vaccine (CSL425)","description":"0.5 mL intramuscular injection on Day 0 and Day 21","armGroupLabels":["CSL425 (15 mcg)"]},{"type":"BIOLOGICAL","name":"CSL's 2009 H1N1 Influenza Vaccine (CSL425)","description":"0.25 mL intramuscular injection on Day 0 and Day 21","armGroupLabels":["CSL425 (7.5 mcg)"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Seroconversion Rate 21 Days After First Study Vaccination","description":"Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.","timeFrame":"21 days after the first study vaccination"},{"measure":"Seroconversion Rate 21 Days After Second Study Vaccination","description":"Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.","timeFrame":"21 days after the second study vaccination"},{"measure":"Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After First Study Vaccination","timeFrame":"21 days after the first study vaccination"},{"measure":"Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After Second Study Vaccination","timeFrame":"21 days after the second study vaccination"}],"secondaryOutcomes":[{"measure":"Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Study Vaccination, Cohort A","description":"Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Cried when limb was moved/spontaneously painful (aged \\< 3 years) for injection site pain; Size \\> 30 mm for injection site redness and injection site induration/swelling; Oral temperature \\> 104.0°F (40.0°C) or axillary temperature \\> 103.1°F (39.5°C) for fevers.","timeFrame":"During the 7 days after each study vaccination"},{"measure":"Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort A","timeFrame":"During the 7 days after each study vaccination"},{"measure":"Frequency and Intensity of Solicited Adverse Events After the First or Second Study Vaccination, Cohort B","description":"Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Prevented normal daily activities (aged \\>= 3 years)for injection site pain; Size \\> 30 mm for injection site redness and injection site induration/swelling; Oral temperature \\> 104.0°F (40.0°C) or axillary temperature \\> 103.1°F (39.5°C) for fevers.","timeFrame":"During the 7 days after each study vaccination"},{"measure":"Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort B","timeFrame":"During the 7 days after each study vaccination"},{"measure":"Frequency and Intensity of Unsolicited Adverse Events (UAE) After the First or Second Vaccination","description":"UAE grading:\n\nGrade 1: Symptoms were easily tolerated and did not interfere with daily activities.\n\nGrade 2: Enough discomfort to cause some interference with daily activities. Grade 3: Symptoms that prevented normal, everyday activities.","timeFrame":"During the 21 days after each vaccination"},{"measure":"Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and New Onset of Chronic Illness (NOCIs)","description":"A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).","timeFrame":"Up to 180 days after the last vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female aged \\>= 6 months to \\< 9 years at the time of the first study vaccination.\n* For children \\< 3 years of age at the time of first vaccination, born at or after 36 weeks gestation.\n\nExclusion Criteria:\n\n* Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"9 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Director Vaccines","affiliation":"Seqirus","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"city":"Melbourne","state":"Florida","zip":"32935","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"city":"Omaha","state":"Nebraska","zip":"68134","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"city":"Austintown","state":"Ohio","zip":"44515","country":"United States","geoPoint":{"lat":41.10172,"lon":-80.76452}},{"city":"Cincinnati","state":"Ohio","zip":"45246","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"city":"Latrobe","state":"Pennsylvania","zip":"15650","country":"United States","geoPoint":{"lat":40.32118,"lon":-79.37948}},{"city":"Pittsburgh","state":"Pennsylvania","zip":"15227","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"city":"Fort Worth","state":"Texas","zip":"76135","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"city":"Murray","state":"Utah","zip":"84107","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years"},{"id":"FG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"FG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"FG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years"},{"id":"FG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"FG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"105"},{"groupId":"FG002","numSubjects":"96"},{"groupId":"FG003","numSubjects":"28"},{"groupId":"FG004","numSubjects":"109"},{"groupId":"FG005","numSubjects":"109"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"99"},{"groupId":"FG002","numSubjects":"82"},{"groupId":"FG003","numSubjects":"25"},{"groupId":"FG004","numSubjects":"100"},{"groupId":"FG005","numSubjects":"99"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"14"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"10"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years"},{"id":"BG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"BG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"BG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years"},{"id":"BG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"BG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"96"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"109"},{"groupId":"BG005","value":"109"},{"groupId":"BG006","value":"473"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"96"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"109"},{"groupId":"BG005","value":"109"},{"groupId":"BG006","value":"473"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.87","spread":"0.77"},{"groupId":"BG001","value":"1.73","spread":"0.72"},{"groupId":"BG002","value":"1.85","spread":"0.66"},{"groupId":"BG003","value":"5.90","spread":"1.71"},{"groupId":"BG004","value":"5.94","spread":"1.71"},{"groupId":"BG005","value":"5.91","spread":"1.70"},{"groupId":"BG006","value":"3.93","spread":"2.45"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"53"},{"groupId":"BG005","value":"50"},{"groupId":"BG006","value":"228"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"56"},{"groupId":"BG005","value":"59"},{"groupId":"BG006","value":"245"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"96"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"109"},{"groupId":"BG005","value":"109"},{"groupId":"BG006","value":"473"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Seroconversion Rate 21 Days After First Study Vaccination","description":"Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.","populationDescription":"The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"21 days after the first study vaccination","groups":[{"id":"OG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years"},{"id":"OG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"OG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"0.1","upperLimit":"20.4"},{"groupId":"OG001","value":"88.2","lowerLimit":"80.4","upperLimit":"93.8"},{"groupId":"OG002","value":"83.1","lowerLimit":"73.7","upperLimit":"90.2"},{"groupId":"OG003","value":"3.7","lowerLimit":"0.1","upperLimit":"19.0"},{"groupId":"OG004","value":"84.6","lowerLimit":"76.2","upperLimit":"90.9"},{"groupId":"OG005","value":"88.2","lowerLimit":"80.4","upperLimit":"93.8"}]}]}]},{"type":"PRIMARY","title":"Seroconversion Rate 21 Days After Second Study Vaccination","description":"Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.","populationDescription":"The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"21 days after the second study vaccination","groups":[{"id":"OG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years"},{"id":"OG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"OG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"98"},{"groupId":"OG005","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","lowerLimit":"11.3","upperLimit":"52.2"},{"groupId":"OG001","value":"98.9","lowerLimit":"94.0","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"95.5","upperLimit":"100.0"},{"groupId":"OG003","value":"15.4","lowerLimit":"4.4","upperLimit":"34.9"},{"groupId":"OG004","value":"98.0","lowerLimit":"92.8","upperLimit":"99.8"},{"groupId":"OG005","value":"99.0","lowerLimit":"94.4","upperLimit":"100.0"}]}]}]},{"type":"SECONDARY","title":"Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Study Vaccination, Cohort A","description":"Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Cried when limb was moved/spontaneously painful (aged \\< 3 years) for injection site pain; Size \\> 30 mm for injection site redness and injection site induration/swelling; Oral temperature \\> 104.0°F (40.0°C) or axillary temperature \\> 103.1°F (39.5°C) for fevers.","populationDescription":"Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"During the 7 days after each study vaccination","groups":[{"id":"OG000","title":"Placebo Cohort A","description":"Placebo"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"96"}]}],"classes":[{"title":"Any local solicited adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"37"}]}]},{"title":"Any pain","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"27"}]}]},{"title":"Grade 3 pain","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any redness","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"19"}]}]},{"title":"Grade 3 redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any swelling / induration","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"6"}]}]},{"title":"Grade 3 swelling / induration","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any systemic solicited adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"65"}]}]},{"title":"Any fever","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"43"}]}]},{"title":"Grade 3 fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}]},{"title":"Any nausea / vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"15"}]}]},{"title":"Grade 3 nausea / vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"38"}]}]},{"title":"Grade 3 diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any loss of appetite","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"}]}]},{"title":"Grade 3 loss of appetite","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any irritability","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"34"}]}]},{"title":"Grade 3 irritability","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort A","populationDescription":"Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.In Cohort A, Safety Population after the first vaccination are placebo group 26, 7.5 mcg group 105 and 15 mcg group 96; and 25, 101 and 91 respectively after the second vaccination.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"During the 7 days after each study vaccination","groups":[{"id":"OG000","title":"Placebo Cohort A","description":"Placebo"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"96"}]}],"classes":[{"title":"Any pain after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.000"},{"groupId":"OG001","value":"1.52","spread":"0.677"},{"groupId":"OG002","value":"1.91","spread":"1.743"}]}]},{"title":"Any redness after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.577"},{"groupId":"OG001","value":"2.20","spread":"1.323"},{"groupId":"OG002","value":"2.56","spread":"1.459"}]}]},{"title":"Any swelling / induration after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.707"},{"groupId":"OG001","value":"1.63","spread":"0.957"},{"groupId":"OG002","value":"2.00","spread":"1.549"}]}]},{"title":"Any fever after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":"3.215"},{"groupId":"OG001","value":"1.32","spread":"0.557"},{"groupId":"OG002","value":"1.29","spread":"0.893"}]}]},{"title":"Any nausea / vomiting after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.000"},{"groupId":"OG001","value":"1.43","spread":"0.535"},{"groupId":"OG002","value":"1.11","spread":"0.333"}]}]},{"title":"Any diarrhea after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":"0.707"},{"groupId":"OG001","value":"2.38","spread":"1.996"},{"groupId":"OG002","value":"3.95","spread":"4.248"}]}]},{"title":"Any loss of appetite after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"NA","comment":"Only one participant reported this AE after the first study vaccination in this group."},{"groupId":"OG001","value":"3.13","spread":"2.500"},{"groupId":"OG002","value":"2.07","spread":"1.486"}]}]},{"title":"Any irritability after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"6.00","spread":"7.810"},{"groupId":"OG001","value":"2.08","spread":"1.412"},{"groupId":"OG002","value":"1.97","spread":"1.224"}]}]},{"title":"Any pain after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"0.787"},{"groupId":"OG001","value":"1.57","spread":"0.676"},{"groupId":"OG002","value":"1.23","spread":"0.599"}]}]},{"title":"Any redness after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"2.608"},{"groupId":"OG001","value":"2.00","spread":"1.240"},{"groupId":"OG002","value":"1.63","spread":"0.916"}]}]},{"title":"Any swelling / induration after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":"NA","comment":"Only one participant reported this AE after the second study vaccination in this group."},{"groupId":"OG001","value":"3.00","spread":"2.098"},{"groupId":"OG002","value":"2.50","spread":"0.707"}]}]},{"title":"Any fever after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.894"},{"groupId":"OG001","value":"1.40","spread":"0.894"},{"groupId":"OG002","value":"2.19","spread":"2.344"}]}]},{"title":"Any nausea / vomiting after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No participants reported this AE after the second study vaccination in this group."},{"groupId":"OG001","value":"1.27","spread":"0.647"},{"groupId":"OG002","value":"1.50","spread":"0.837"}]}]},{"title":"Any diarrhea after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"8.00","spread":"9.899"},{"groupId":"OG001","value":"1.92","spread":"1.248"},{"groupId":"OG002","value":"4.33","spread":"6.754"}]}]},{"title":"Any loss of appetite after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.707"},{"groupId":"OG001","value":"1.75","spread":"1.183"},{"groupId":"OG002","value":"3.60","spread":"5.168"}]}]},{"title":"Any irritability after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.577"},{"groupId":"OG001","value":"1.81","spread":"1.001"},{"groupId":"OG002","value":"2.86","spread":"4.597"}]}]}]},{"type":"SECONDARY","title":"Frequency and Intensity of Solicited Adverse Events After the First or Second Study Vaccination, Cohort B","description":"Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Prevented normal daily activities (aged \\>= 3 years)for injection site pain; Size \\> 30 mm for injection site redness and injection site induration/swelling; Oral temperature \\> 104.0°F (40.0°C) or axillary temperature \\> 103.1°F (39.5°C) for fevers.","populationDescription":"Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"During the 7 days after each study vaccination","groups":[{"id":"OG000","title":"Placebo Cohort B","description":"Placebo"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"109"}]}],"classes":[{"title":"Any local solicited adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"49"}]}]},{"title":"Any pain","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"40"}]}]},{"title":"Grade 3 pain","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any redness","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"26"}]}]},{"title":"Grade 3 redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any swelling / induration","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"17"}]}]},{"title":"Grade 3 swelling / induration","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any systemic solicited adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"46"}]}]},{"title":"Any fever","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"}]}]},{"title":"Grade 3 fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any nausea / vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"13"}]}]},{"title":"Grade 3 nausea / vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}]}]},{"title":"Grade 3 diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any headache","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"25"}]}]},{"title":"Grade 3 headache","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any malaise","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"20"}]}]},{"title":"Grade 3 malaise","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"22"}]}]},{"title":"Grade 3 myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After First Study Vaccination","populationDescription":"The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"21 days after the first study vaccination","groups":[{"id":"OG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years"},{"id":"OG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"OG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"1.0","upperLimit":"26.0"},{"groupId":"OG001","value":"90.2","lowerLimit":"82.7","upperLimit":"95.2"},{"groupId":"OG002","value":"84.3","lowerLimit":"75.0","upperLimit":"91.1"},{"groupId":"OG003","value":"25.9","lowerLimit":"11.1","upperLimit":"46.3"},{"groupId":"OG004","value":"84.6","lowerLimit":"76.2","upperLimit":"90.9"},{"groupId":"OG005","value":"89.2","lowerLimit":"81.5","upperLimit":"94.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After Second Study Vaccination","populationDescription":"The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"21 days after the second study vaccination","groups":[{"id":"OG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years"},{"id":"OG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"OG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"98"},{"groupId":"OG005","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","lowerLimit":"11.3","upperLimit":"52.2"},{"groupId":"OG001","value":"98.9","lowerLimit":"94.0","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"95.5","upperLimit":"100.0"},{"groupId":"OG003","value":"34.6","lowerLimit":"17.2","upperLimit":"55.7"},{"groupId":"OG004","value":"98.0","lowerLimit":"92.8","upperLimit":"99.8"},{"groupId":"OG005","value":"100.0","lowerLimit":"96.3","upperLimit":"100.0"}]}]}]},{"type":"SECONDARY","title":"Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort B","populationDescription":"Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data. In Cohort B, Safety Population after the first vaccination are placebo group 28, 7.5 mcg group 107 and 15 mcg group 109; and 27, 105 and 103 respectively after the second vaccination.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"During the 7 days after each study vaccination","groups":[{"id":"OG000","title":"Placebo Cohort B","description":"Placebo"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"109"}]}],"classes":[{"title":"Any pain after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"0.516"},{"groupId":"OG001","value":"1.63","spread":"1.066"},{"groupId":"OG002","value":"1.46","spread":"0.691"}]}]},{"title":"Any redness after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"1.254"},{"groupId":"OG001","value":"2.17","spread":"1.339"},{"groupId":"OG002","value":"2.24","spread":"1.809"}]}]},{"title":"Any swelling / induration after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"1.732"},{"groupId":"OG001","value":"1.80","spread":"0.632"},{"groupId":"OG002","value":"1.79","spread":"0.975"}]}]},{"title":"Any fever after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"0.447"},{"groupId":"OG001","value":"1.12","spread":"0.332"},{"groupId":"OG002","value":"1.56","spread":"0.856"}]}]},{"title":"Any nausea / vomiting after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.000"},{"groupId":"OG001","value":"1.25","spread":"0.500"},{"groupId":"OG002","value":"1.00","spread":"0.000"}]}]},{"title":"Any diarrhea after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"0.354"},{"groupId":"OG001","value":"1.00","spread":"0.000"},{"groupId":"OG002","value":"1.22","spread":"0.441"}]}]},{"title":"Any malaise after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"0.744"},{"groupId":"OG001","value":"1.47","spread":"0.964"},{"groupId":"OG002","value":"1.60","spread":"0.995"}]}]},{"title":"Any myalgia after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"0.548"},{"groupId":"OG001","value":"1.42","spread":"0.669"},{"groupId":"OG002","value":"1.56","spread":"0.984"}]}]},{"title":"Any headache after first vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.894"},{"groupId":"OG001","value":"1.15","spread":"0.376"},{"groupId":"OG002","value":"1.25","spread":"0.645"}]}]},{"title":"Any pain after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.500"},{"groupId":"OG001","value":"1.56","spread":"0.856"},{"groupId":"OG002","value":"1.33","spread":"0.555"}]}]},{"title":"Any redness after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"0.000"},{"groupId":"OG001","value":"1.67","spread":"0.516"},{"groupId":"OG002","value":"1.60","spread":"0.699"}]}]},{"title":"Any swelling / induration after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"NA","comment":"Only one participant reported this AE after the second study vaccination in this group."},{"groupId":"OG001","value":"1.17","spread":"0.408"},{"groupId":"OG002","value":"1.63","spread":"0.744"}]}]},{"title":"Any fever after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"NA","comment":"Only one participant reported this AE after the second study vaccination in this group."},{"groupId":"OG001","value":"1.40","spread":"0.548"},{"groupId":"OG002","value":"1.57","spread":"1.134"}]}]},{"title":"Any nausea / vomiting after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"NA","comment":"Only one participant reported this AE after the second study vaccination in this group."},{"groupId":"OG001","value":"1.25","spread":"0.500"},{"groupId":"OG002","value":"1.17","spread":"0.408"}]}]},{"title":"Any diarrhea after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"NA","comment":"Only one participant reported this AE after the second study vaccination in this group."},{"groupId":"OG001","value":"1.00","spread":"0.000"},{"groupId":"OG002","value":"1.00","spread":"0.000"}]}]},{"title":"Any malaise after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.707"},{"groupId":"OG001","value":"1.75","spread":"0.754"},{"groupId":"OG002","value":"1.83","spread":"1.467"}]}]},{"title":"Any myalgia after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"NA","comment":"Only one participant reported this AE after the second study vaccination in this group."},{"groupId":"OG001","value":"1.38","spread":"0.518"},{"groupId":"OG002","value":"1.42","spread":"0.669"}]}]},{"title":"Any headache after second vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.707"},{"groupId":"OG001","value":"1.38","spread":"0.518"},{"groupId":"OG002","value":"1.29","spread":"0.488"}]}]}]},{"type":"SECONDARY","title":"Frequency and Intensity of Unsolicited Adverse Events (UAE) After the First or Second Vaccination","description":"UAE grading:\n\nGrade 1: Symptoms were easily tolerated and did not interfere with daily activities.\n\nGrade 2: Enough discomfort to cause some interference with daily activities. Grade 3: Symptoms that prevented normal, everyday activities.","populationDescription":"Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"During the 21 days after each vaccination","groups":[{"id":"OG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years"},{"id":"OG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"OG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"96"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"107"},{"groupId":"OG005","value":"109"}]}],"classes":[{"title":"Proportion of participants with at least one UAE","categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"49"},{"groupId":"OG005","value":"41"}]}]},{"title":"Proportion of participants reported Grade 1 UAE","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"19"}]}]},{"title":"Proportion of participants reported Grade 2 UAE","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"17"}]}]},{"title":"Proportion of participants reported Grade 3 UAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"}]}]}]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and New Onset of Chronic Illness (NOCIs)","description":"A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).","populationDescription":"Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 180 days after the last vaccination","groups":[{"id":"OG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years"},{"id":"OG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years"},{"id":"OG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years"},{"id":"OG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"},{"id":"OG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"96"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"107"},{"groupId":"OG005","value":"109"}]}],"classes":[{"title":"Proportion of participants with at least one SAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Proportion of participants with related SAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Proportion of participants with at least one AESI","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Proportion of participants with related AESI","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Proportion of participants with at least one NOCI","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Proportion of participants with related NOCI","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"180 days after the last study vaccination for SAEs. 21 days after each study vaccination for unsolicited adverse events.","description":"Other adverse events presented are unsolicited adverse events 21 days after either study vaccination.","eventGroups":[{"id":"EG000","title":"Placebo Cohort A","description":"Placebo, Aged 6 months to less than 3 years","seriousNumAffected":0,"seriousNumAtRisk":26,"otherNumAffected":25,"otherNumAtRisk":26},{"id":"EG001","title":"CSL425 (7.5 mcg) Cohort A","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years","seriousNumAffected":2,"seriousNumAtRisk":105,"otherNumAffected":58,"otherNumAtRisk":105},{"id":"EG002","title":"CSL425 (15 mcg) Cohort A","description":"15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years","seriousNumAffected":3,"seriousNumAtRisk":96,"otherNumAffected":82,"otherNumAtRisk":96},{"id":"EG003","title":"Placebo Cohort B","description":"Placebo, Aged 3 years to less than 9 years","seriousNumAffected":0,"seriousNumAtRisk":28,"otherNumAffected":22,"otherNumAtRisk":28},{"id":"EG004","title":"CSL425 (7.5 mcg) Cohort B","description":"7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years","seriousNumAffected":0,"seriousNumAtRisk":107,"otherNumAffected":70,"otherNumAtRisk":107},{"id":"EG005","title":"CSL425 (15 mcg) Cohort B","description":"15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years","seriousNumAffected":0,"seriousNumAtRisk":109,"otherNumAffected":49,"otherNumAtRisk":109}],"seriousEvents":[{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]},{"term":"Pneumonia viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]}],"otherEvents":[{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":105},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":96},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]},{"term":"Rhinorrhea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":26},{"groupId":"EG001","numEvents":19,"numAffected":17,"numAtRisk":105},{"groupId":"EG002","numEvents":17,"numAffected":14,"numAtRisk":96},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG004","numEvents":8,"numAffected":6,"numAtRisk":107},{"groupId":"EG005","numEvents":7,"numAffected":7,"numAtRisk":109}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":26},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":105},{"groupId":"EG002","numEvents":21,"numAffected":17,"numAtRisk":96},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG004","numEvents":22,"numAffected":21,"numAtRisk":107},{"groupId":"EG005","numEvents":17,"numAffected":15,"numAtRisk":109}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":105},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":96},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":107},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":109}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":105},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":107},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":109}]},{"term":"Teething","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":105},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":105},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":96},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":107},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":109}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":26},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":105},{"groupId":"EG002","numEvents":15,"numAffected":14,"numAtRisk":96},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":28},{"groupId":"EG004","numEvents":17,"numAffected":15,"numAtRisk":107},{"groupId":"EG005","numEvents":11,"numAffected":10,"numAtRisk":109}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":105},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":96},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG005","numEvents":5,"numAffected":3,"numAtRisk":109}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":105},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":96},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":107},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":109}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":96},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":28},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":107},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":109}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Clinical Study Disclosure Manager","organization":"Seqirus","email":"Seqirus.ClinicalTrials@Seqirus.com","phone":"1-855-358-8966"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}